drugset / Trial / NCT07694986
Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD
Phase 2
Recruiting
30 enrolled
H. Lee Moffitt Cancer Center and Research Institute
United States Department of Defense · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), in combination with trastuzumab or nivolumab to confirm the highest dose of the study treatment that can be given safely to participants with Breast Cancer (BC) with Leptomeningeal Disease (LMD).
Timeline
- Start
- 2026-08
- Primary completion
- 2029-08
- Completion
- 2030-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC vaccine | Vaccine | — | Intrathecal |
| Subject | Nivolumab | Monoclonal antibody | 50 mg | Intrathecal |
| Subject | Trastuzumab | Monoclonal antibody | 150 mg | Intrathecal |